KRAS and BRAF genotyping of synchronous colorectal carcinomas

KRAS and BRAF genotyping of synchronous colorectal carcinomas

v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) genotyping is required prior to anti-epidermal growth factor receptor monoclonal antibody therapy administered in cases of metastatic colorectal carcinoma (CRC). Thus, KRAS mutation screening is required for patient management. The present...

Full description

Bibliographic Details
Main Authors:	GIANNINI, RICCARDO, LUPI, CRISTIANA, LOUPAKIS, FOTIOS, SERVADIO, ADELE, CREMOLINI, CHIARA, SENSI, ELISA, CHIARUGI, MASSIMO, ANTONIOTTI, CARLOTTA, BASOLO, FULVIO, FALCONE, ALFREDO, FONTANINI, GABRIELLA
Format:	Online
Language:	English
Published:	D.A. Spandidos 2014
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3997682/

Similar Items

The Winding Roadmap of Biomarkers Toward Clinic: Lessons from Predictors of Resistance to Anti-EGFRs in Metastatic Colorectal Cancer
by: Carlotta Antoniotti, et al.
Published: (2018-08-01)

BRAF-mutated metastatic colorectal cancer between past and future
by: Cremolini, Chiara, et al.
Published: (2015)

Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer
by: Loupakis, Fotios, et al.
Published: (2016)

Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer
by: Fornaro, Lorenzo, et al.
Published: (2015)

P2X7 protein expression and polymorphism in non-small cell lung cancer (NSCLC)
by: Boldrini, Laura, et al.
Published: (2014)

BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection
by: Schirripa, M, et al.
Published: (2015)

Prognostic Significance of C-Reactive Protein Polymorphism and KRAS/BRAF in Synchronous Liver Metastasis from Colorectal Cancer
by: Huang, Chi-Jung, et al.
Published: (2013)

KRAS/BRAF Analysis in Ovarian Low-Grade Serous Carcinoma Having Synchronous All Pathological Precursor Regions
by: Nakamura, Kohei, et al.
Published: (2016)

Molecular Diagnostics of Fine Needle Aspiration for the Presurgical Screening of Thyroid Nodules
by: Fallahi, Poupak, et al.
Published: (2014)

Are KRAS/BRAF Mutations Potent Prognostic and/or Predictive Biomarkers in Colorectal Cancers?
by: Yokota, Tomoya
Published: (2012)

Frequent mutations of KRAS in addition to BRAF in colorectal serrated adenocarcinoma
by: Stefanius, Karoliina, et al.
Published: (2011)

The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer
by: Eklöf, V, et al.
Published: (2013)

EGFR Expression and KRAS and BRAF Mutational Status in Intestinal-Type Sinonasal Adenocarcinoma
by: Szablewski, Vanessa, et al.
Published: (2013)

Context-dependent interpretation of the prognostic value of BRAF and KRAS mutations in colorectal cancer
by: Popovici, Vlad, et al.
Published: (2013)

EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas
by: BUJKO, MATEUSZ, et al.
Published: (2014)

The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients
by: Daeyoun David Won, et al.
Published: (2017-06-01)

Molecular pathological epidemiology of colorectal cancer in Chinese patients with KRAS and BRAF mutations
by: Li, Wenbin, et al.
Published: (2015)

KRAS and BRAF mutational status in colon cancer from Albanian patients
by: Martinetti, Daniela, et al.
Published: (2014)

KRAS, BRAF and PIK3CA Status in Squamous Cell Anal Carcinoma (SCAC)
by: Casadei Gardini, Andrea, et al.
Published: (2014)

Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab
by: Loupakis, F, et al.
Published: (2013)

Do we need biopsies of metastases for colorectal cancer patients?
by: Floriani, I, et al.
Published: (2009)

Reply: Comment on ‘Histopathologic evaluation of liver metastases from colorectal cancer patients treated with FOLFOXIRI plus bevacizumab'
by: Schirripa, M, et al.
Published: (2013)

Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation
by: Lionetti, Marta, et al.
Published: (2015)

Response to erlotinib in a patient with lung adenocarcinoma harbouring the EML4-ALK translocation: A case report
by: ALÌ, GRETA, et al.
Published: (2015)

High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer
by: Guedes, Joana G, et al.
Published: (2013)

Fr-MLV infection induces erythroleukaemia instead of lymphoid leukaemia in mice given pituitary grafts.
by: Fontanini, G., et al.
Published: (1990)

KRAS, BRAF and PIK3CA Mutations and the Loss of PTEN Expression in Chinese Patients with Colorectal Cancer
by: Mao, Chen, et al.
Published: (2012)

Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing
by: Borràs, Emma, et al.
Published: (2011)

Antitumoral Efficacy of the Protease Inhibitor Gabexate Mesilate in Colon Cancer Cells Harbouring KRAS, BRAF and PIK3CA Mutations
by: Brandi, Giovanni, et al.
Published: (2012)

Pyrosequencing data analysis software: a useful tool for EGFR, KRAS, and BRAF mutation analysis
by: Shen, Shanxiang, et al.
Published: (2012)

A New Microarray Substrate for Ultra-Sensitive Genotyping of KRAS and BRAF Gene Variants in Colorectal Cancer
by: Galbiati, Silvia, et al.
Published: (2013)

Rare Though Not Mutually Exclusive: A Report of Three Cases of Concomitant KRAS and BRAF Mutation and a Review of the Literature
by: Sahin, Ibrahim Halil, et al.
Published: (2013)

Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery
by: Derbel, Olfa, et al.
Published: (2013)

Validation of Next Generation Sequencing Technologies in Comparison to Current Diagnostic Gold Standards for BRAF, EGFR and KRAS Mutational Analysis
by: McCourt, Clare M., et al.
Published: (2013)

Sex differences in the prognostic significance of KRAS codons 12 and 13, and BRAF mutations in colorectal cancer: a cohort study
by: Wangefjord, Sakarias, et al.
Published: (2013)

P53, MAPK, topoisomerase II alpha and Ki67 immunohistochemical expression and KRAS/BRAF mutation in ovarian serous carcinomas
by: Sundov, Dinka, et al.
Published: (2013)

Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer
by: Takahashi, Naoki, et al.
Published: (2014)

KRAS, BRAF genotyping reveals genetic heterogeneity of ovarian borderline tumors and associated implants
by: Heublein, Sabine, et al.
Published: (2013)

KRAS and BRAF Mutations in 203 Esophageal Squamous Cell Carcinomas: Pyrosequencing Technology and Literature Review
by: Shigaki, Hironobu, et al.
Published: (2012)

EGFR, KRAS, BRAF, and HER-2 molecular status in brain metastases from 77 NSCLC patients
by: Villalva, Claire, et al.
Published: (2013)